Table 3.

Scenarios for different proportions of PPCs produced^*

Percent PPCs of total PCs produced	10	20	30	40	50	60	70	80	90	100
Percent of annual WBDs used for production of PPCs	5	10	15	20	25	30	35	40	45	50
Estimated number of WBDs lost annually	11,552−	23,104−	34,656−	46,207−	57,759−	69,311−	80,863−	92,415−	103,967−	115,519−
	23,104	46,207	69,311	92,415	115,519	138,622	161,726	184,830	207,934	231,037
Estimated number of RBCs lost annually	10,905−	21,810−	32,715−	43,619−	54,524−	65,430−	76,335−	87,240−	98,145−	114,826−
	21,810	43619	65,430	87,240	109,050	130859	152669	174,480	196,290	218099
Estimated percentage of annual RBCs lost, %	0.25–0.5	0.5–1.0	0.75–1.5	1,0–2.0	1,25–2.5	1.5–3.0	1.75–3.5	2.0–4.0	2.25–4.5	2.5–5.0
Decay at the producer: number of PCs	35,649	39,357	43,066	46,774	50,481	54,189	57,898	61,606	65,314	69,022

^*In Germany, total WBDs in 2013 were 4,631,290 used for the production of 4,371,743 RBCs (94.4% of WBDs). Total production of PCs was 577,593 units [13]. It is assumed that losses of erythrocytes due to production of buffy coats for PPC production from WBDs amount to 5–10% of the WBDs used [14]. The number of WBDs lost annually, as well as the corresponding number of RBCs otherwise produced from these WBDs can be calculated. As a function of the proportion of PPCs produced the percentage of WBDs used for production of PPCs changes. As a result also the estimated number and percentage of annual RBCs lost due to production of buffy coat derived PPCs are changed. Due to different rates of decay at the producer for PPCs and APCs the overall rate of platelet concentrate decay changes as well (table 2).